We have previously demonstrated that peroxisome proliferator-activated receptor (PPARg) activation inhibits hepatocarcinogenesis. We aim to investigate the effect of PPARg on hepatocellular carcinoma (HCC) metastatic potential and explore its underlying mechanisms. METHODS: Human HCC cells (MHCC97L, BEL-7404) were infected with adenovirus-expressing PPARg (Ad-PPARg) or Ad-lacZ and treated with or without PPARg agonist (rosiglitazone). The effects of PPARg on cell migration and invasive activity were determined by wound healing assay and Matrigel invasive model in vitro, and in an orthotopic liver tumour metastatic model in mice. RESULTS: Pronounced expression of PPARg was demonstrated in HCC cells (MHCC97L, BEL-7404) treated with Ad-PPARg, rosiglitazone or Ad-PPARg plus rosiglitazone, compared with control (Ad-LacZ). Such induction markedly suppressed HCC cell migration. Moreover, the invasiveness of MHCC97L and BEL-7404 cells infected with Ad-PPARg, or treated with rosiglitazone was significantly diminished up to 60%. Combination of Ad-PPARg and rosiglitazone showed an additive effect. Activation of PPARg by rosiglitazone significantly reduced the incidence and severity of lung metastasis in an orthotopic HCC mouse model. Key mechanisms underlying the effect of PPARg in HCC include upregulation of cell adhesion genes, E-cadherin and SYK (spleen tyrosine kinase), extracellular matrix regulator tissue inhibitors of metalloproteinase (TIMP) 3, tumour suppressor gene retinoblastoma 1, and downregulation of pro-metastatic genes MMP9 (matrix metallopeptidase 9), MMP13, HPSE (heparanase), and Hepatocyte growth factor (HGF). Direct transcriptional regulation of TIMP3, MMP9, MMP13, and HPSE by PPARg was shown by ChIP-PCR. CONCLUSION: Peroxisome proliferator-activated receptor-gamma exerts an inhibitory effect on the invasive and metastatic potential of HCC in vitro and in vivo, and is thus, a target for the prevention and treatment of HCC metastases.
Despite significant advances in early detection and therapy, hepatocellular carcinoma (HCC) still remains the third leading cause of cancer-related deaths worldwide (Bosch et al, 2004) . The high mortality rate of HCC is mainly attributable to late presentation at advanced stage, where curative surgical resection is no longer feasible or of limited efficacy (Mann et al, 2007) . Tumour recurrence in HCC can occur as metastases, whereas more than 90% of HCC-related deaths are the result of secondary local or distant disease. However, efficacious or curative drug therapy for HCC and its metastases remains elusive.
Peroxisome proliferator-activated receptor-gamma (PPARg) is a ligand-activated transcription factor that belongs to the nuclear hormone receptor super family; its roles include control of several biological processes related to growth, differentiation, cell cycle, and apoptosis (Koeffler 2003) . Activation of PPARg has been shown to inhibit proliferation in several cancers in vitro and in vivo (Koeffler 2003; Grommes et al, 2004) . Our group has recently reported that PPARg activation by its agonist (Yu et al, 2006) or ectopic expression of PPARg by Ad-PPARg transfection (Yu et al, 2010) inhibits HCC growth and progression by suppressing cell proliferation, inducing cell apoptosis, and causing cell cycle arrest (Yu et al, 2006 (Yu et al, , 2010 . The PPARg expression in HCC is significantly reduced in tumour tissues compared with surrounding non-tumourous liver, especially in poorly differentiated tumour than in well-differentiated tumour (Yu et al, 2006) . Peroxisome proliferator-activated receptor-gamma also has a role in inhibiting tumour growth and metastatic spread in colon (Takano et al, 2008) and thyroid cancers (Ohta et al, 2001; Chen et al, 2006) as well as lung carcinoma (Panigrahy et al, 2002) . However, PPAR's effect on invasive and metastatic potential of HCC has yet to be defined.
The aim of the present study was to determine the effect and the underlying molecular mechanism of PPARg on HCC cell migration and invasion using HCC cell lines and formation of distant metastases in vivo in an orthotopic murine liver tumour model.
MATERIALS AND METHODS

Human HCC cell lines and culture
The human HCC cell line MHCC97L, stably labelled with luciferase, was a gift from K Man, Department of Surgery, The University of Hong Kong (Man et al, 2010) . BEL-7404 was obtained from the Institute of Biochemistry and Cell Biology (SIBS, Shanghai, China) (Chen et al, 1980) . Cells were cultured in DMEM (Dulbecco's modified Eagle medium) supplemented with 10% foetal bovine serum (Invitrogen, Carlsbad, CA, USA) and incubated at 37 1C and 5% CO 2 .
Adenovirus-mediated PPARc gene transfer
Recombinant adenovirus expressing the mouse PPARg-1 cDNA (Ad-PPARg) or E. coli b-galactosidase gene (Ad-LacZ, control adenovirus vector) (gift from JK Reddy, Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago) was propagated, isolated in human embryonic kidney 293 (HEK293) cells, then purified with Adeno-X Maxi Purification Kit (Clontech, Mountain View, CA, USA); the adeno virus with infectious titre range from 1.0 Â 10 9 to 10 10 pfu (plaque-forming unit) ml À 1 was stored at À 80 1C until use.
RNA extraction, cDNA synthesis, and RT-PCR
Total RNA was extracted from cell pellets by Trizol (Invitrogen) and reverse transcribed into cDNA using MultiScribe Reverse Transcriptase (Applied Biosystems, Foster city, CA, USA) according to the manufacturer's instructions. The target gene expression was determined by RT-PCR using specific primers of target genes (Table 1) . GAPDH was served as an internal control for total cDNA content. Samples were amplified using the ABI Prism 7700 Sequence Detection System (Applied Biosystems).
Tumour cell migration assay
Wound healing assay was performed for analysis of cell migration in vitro. Briefly, MHCC97L (5 Â 10 5 cells per well) or BEL-7404 (5 Â 10 5 cells per well) cells were seeded in 12-well plates and infected with Ad-LacZ (70 multiplicities of infection, MOI) or Ad-PPARg (70 MOI), and treated with or without rosiglitazone (50 mM) at 37 o C until 90% confluent (Yu et al, 2010) . Sterile tips were used to scratch cell layers, which were subsequently washed with PBS, and cultured with DMEM media and 1% FBS. Cells were photographed (phase-contrast microscope) at 0, 24, 36, and 48 h after incubation. The distance travelled by cells was measured between the two boundaries of an acellular area and results of treatment groups expressed as a ratio to Ad-Lacz-treated cells. Each experiment was performed in triplicate.
Tumour cells invasion assay
Matrigel invasion assay (Becton Dickinson, Waltham, MA, USA) was performed as previously described (Yu et al, 2009 ). MHCC97L and BEL-7404 cells infected with Ad-PPARg or Ad-LacZ (2.5 Â 10 4 per well) treated with or without rosiglitazone (a selective PPARg agonist) at 0, 24, 36, and 48 h, then harvested and added into the trans-well containing 600 ml DMEM media and 10% FBS in the lower chamber. After 48 h, cells that had invaded through the Matrigel membrane were stained with crystal violet, and counted (four high-power fields, Â 100 magnification). Experiments were conducted in triplicate.
Orthotopic murine liver tumour model of distant metastasis
An orthotopic HCC metastasis mouse model was established using MHCC97L, which has metastatic potential to lung (Man et al, 2010) . MHCC97L cells (2 Â 10 6 cells in 0.1 ml PBS) were injected subcutaneously into the left dorsal flank of 4-week-old male Balb/c nude mice. Subcutaneous tumours were harvested once the subcutaneous tumours reached about 10 mm 3 and cut into 1.0 mm 3 pieces. One piece of tumour was then implanted into the left liver lobes in a separate group of nude mice (6-week-old) (10 per group) (Man et al, 2010) . After tumour implantation, mice were randomly treated with or without rosiglitazone (200 p.p.m. in chow), a dosage was selected base on our previous experiments (Yu et al, 2010) . Liver tumour growth and lung metastasis were monitored by Xenogen IVIS-200, an optical in vivo imaging system (Caliper Life Science, Hopkinton, MA, USA) weekly. Mice were euthanised at week 7 after tumour implantation (Man et al, 2010) , tumours and lung nodules were analysed histologically. Signal intensity of tumours detected by Xenogen IVIS was expressed as Radiant Efficiency (radiance/illumination power density ¼ p s
). All experimental procedures were approved by the Animal Ethics Committee of the Chinese University of Hong Kong.
cDNA expression array
Gene expression profiles were analysed by the Human Tumour Metastasis PCR Array according to the protocol (SABiosciences, Frederick, MD, USA). Briefly, total RNA was extracted from MHCC97L cells infection with Ad-PPARg (70 MOI) or Ad-LacZ (70 MOI) (control) for 48 h. One mg of total RNA was treated and cDNA was prepared using RT 2 First Strand Kit (SABiosciences). Pairs of test and control samples were mixed with RT 2 qPCR Master mix, distributed to PCR array in 96-well plates, cycling with real-time PCR. Each array contained 84 genes with ascribed functions related to metastasis pathways. Data were analysed using SABiosciences software. Genes with fold-changes more than or less than 1.5 were considered to be of biological significance.
Chromatin immunoprecipitation (ChIP) assay
Chromatin immunoprecipitation analysis was performed using Red ChIP Kit (Diagenode, Liège, Belgium). After transfection with Ad-PPARg (70 MOI) or Ad-LacZ (70 MOI) for 48 h, MHCC97L cells were fixed and collected for ChIP assay. DNA-protein complexes were precipitated using specific antibody of PPARg (Santa Cruz Biotechnology, Santa Cruz, CA, USA). DNA fragments were decross-linked and purified from complexes; immunoprecipitated and input DNA were used as templates for ChIP-PCR.
Characterisation of PPARc-binding region and semi-quantitatation of ChIP-PCR
To evaluate the direct modulation of transcriptional activity on the promoters of metastasis-related genes by PPARg, the Genomatix tool, ModelInspector, was used to scan all the known PPARgbinding regions linked to metastasis-related genes. Human promoter regions (size between 2 kb) in the Genomatix promoter database were scanned. Matched binding sites were selected with core and matrix similarity of 40.8 (http://www.genomatix.de/ online_help/help_matinspector/matinspector_help.html). The predicted PPARg-binding sites on the promoter of target genes were validated by ChIP-PCR (specific primers listed in Table 1 ).
Western blot analysis
Total protein was extracted from cell pellets and protein concentration measured by Bradford assay (Bio-Rad, Hercules, CA, USA). A total of 30 mg of protein was separated by 12% sodium dodecyl sulphate-polyacrylamide gel electrophoresis, then transferred onto equilibrated polyvinylidene difluoride membrane (Amersham Biosciences, Buckinghamshire, UK). Membranes were probed with primary antibodies for tissue inhibitors of metalloproteinase 3 (TIMP3), heparanase (HPSE), and E-cadherin (Santa Cruz Biotechnology).
Statistical analysis
Data were presented as means±s.d. Multiple group comparisons were analysed by one-way ANOVA after Bonferroni's correction. Non-parametric data between two groups was computed by Chi-square test or Fisher Exact test. The difference for two different groups was determined by Student's t test. A P-value of less than 0.05 was considered statistically significant.
RESULTS
Peroxisome proliferator-activated receptor-gamma suppresses HCC cell migration and invasiveness of MHCC97L and BEL-7404 human HCC cell lines
The MHCC97L and BEL-7404 cells were infected with Ad-PPARg or Ad-LacZ (control) in the presence or absence of rosiglitazone for 48 h and induction of PPARg was confirmed by Western blot ( Figure 1A ). Enhanced PPARg expression by Ad-PPARg or rosiglitazone, markedly slowed cell migration scratchy 'wound' at edges of MHCC97L and BEL-7404 HCC cells ( Figure 1B) . Quantitative analyses at 36 h confirmed a significant reduction in wound closure in Ad-PPARg or rosiglitazone-treated cells compared with Ad-LacZ-infected control cells ( Figure 1C ). There appeared to be an additive effect of Ad-PPARg plus rosilitazone compared with Ad-PPARg or rosiglitazone only in BEL-7404 cell line ( Figure 1C) .
To study the effect of PPARg conferred on the invasiveness of HCC, MHCC97L and BEL-7404 cells were infected with Ad-PPARg, or treated with rosiglitazone using a Matrigel model (Figure2A). In vitro invasively growing HCC cells were significantly impaired by up to 60% when infected with Ad-PPARg or primed by rosiglitazone at 48 h ( Figure 2B ). Moreover, the combination of Ad-PPARg and rosiglitazone incrementally suppressed cell invasion compared with Ad-PPARg or rosiglitazone alone ( Figure 2B ).
Activation of PPARc by rosiglitazone inhibits HCC metastases to the lung in vivo
In light of the observed anti-migration and anti-invasion effects of PPARg on HCC cell lines in vitro, we tested whether activation of PPARg by rosiglitazone could alter metastatic potential of MHCC97L in vivo in an orthotopic metastasis mouse model, where subcutaneously grown tumours derived from MHCC97L cells expressing luciferase were implanted into the livers of nude mice; small successful transplantation of tumours were confirmed by xenogen imaging 2 weeks after surgery ( Figure 3A ). Mice were randomly treated with rosiglitazone or vehicle for 7 weeks and then re-imaged in vivo. By week 7, 87.5% (7 out of 8) of the vehicle-treated control mice demonstrated lung metastases after orthotopic implantation. In contrast, only 33% (3 out of 9) of rosiglitazonetreated animals developed lung metastases (Po 0.05) ( Figure 3B ). The luciferase signals emanating from the lungs originally from the MHCC97L cells expressing luciferase in the rosiglitazone-treated mice were significantly lower than in the vehicle-treated group (1.7 Â 10 5 vs 3.14 Â 10 6 p s
, Po 0.05) ( Figure 3C ). Subsequent histology confirmed that lung nodules were secondary/ metastatic deposits from liver ( Figure 3B ). Collectively, these results provide clear evidence that PPARg activation inhibits lung metastasis in an orthotopic HCC model in vivo.
Peroxisome proliferator-activated receptor-gamma modulates the expression profiles of metastasis-related genes in MHCC97L cells
To elucidate the molecular mechanisms underlying the inhibitory effect of PPARg on HCC cell invasiveness, gene expression profiles in Ad-PPARg-infected MHCC97L were analysed using a human tumour metastasis pathway PCR array. When compared with control Ad-LacZ-infected cells, PPARg altered downstream targets involved in cell adhesion, extracellular matrix (ECM) proteins, cell growth, and cell motility (Table 2) , all of which are critical to the regulation of cancer cell invasiveness and metastasis. Peroxisome proliferator-activated receptor-gamma exerted its anti-metastatic effects by increasing the expression of cell adhesion genes, E-cadherin (5.2-fold), spleen tyrosine kinase (SYK) (1.7-fold), and ECM regulator metallopeptidase inhibitor 3 (TIMP3) (7.2-fold), a physiological inhibitor of matrix metallopeptidases (MMPs). The PPARg also suppressed expression of pro-metastatic genes, such as MMP9 ( À 1.7-fold), MMP13 ( À 2.0-fold), HPSE ( À 6.5-fold), and significantly diminished hepatocyte growth factor (HGF) ( À 2.2-fold), a cellular growth and motility regulator. Further, PPARg-induced retinoblastoma 1 (RB1) expression, a potent tumour suppressor gene by four-fold (Table 2) .
To validate these changes on expression profiling, western blot and semi-quantitative RT-PCR were performed on MHCC97L and BEL-7404 cells infected with Ad-PPARg or Ad-LacZ in the presence or absence of rosiglitazone. Ectopic expression of PPARg by AdPPARg or activation of PPARg by rosiglitazone, increased E-cadherin and TIMP3 protein expression with a concomitant diminution of HPSE in both HCC cell lines ( Figure 4A1 ). Combination of Ad-PPARg and rosiglitazone exerted an additive effect on the induction of E-cadherin and TIMP3 and suppression of HPSE ( Figure 4A1 ). A similar enhanced suppressive effect of the combination of Ad-PPARg and rosiglitazone was observed on MMP9 and MMP13 mRNA expression by RT-PCR ( Figure 4A2 ).
Direct transcriptional regulation of TIMP3, MMP9, MMP13, and HPSE by PPARc
To further determine whether PPARg-mediated downstream gene expression changes were associated with direct promoter binding, PPARg-binding sites in the promoters of identified targets, TIMP3, MMP9, MMP13, and HPSE, were mined using ModelInspector software (Genomatix Software GmbH, Munich, Germany). Chromatin immunoprecipitation assay with PPARg antibody was performed in MHCC97L cells followed by PCR confirmation ( Figure 4B 
DISCUSSION
The significance of PPARg on the process of metastasis is not well studied in contrast to the effect of PPARg on tumour growth. In this study, we show that ectopic expression of PPARg by Ad-PPAR or its agonist, rosiglitazone, in two HCC cell lines (MHCC97L, BEL-7404) inhibits metastatic activity in vitro, in particular in wound healing, cell migration, and invasion. Moreover, the combination of Ad-PPARg and rosiglitazone results in an enhanced anti-metastatic effect. Together, these results indicate that restoration of PPARg allow for interactions with endogenous or exogenous agonists that activate the anti-metastatic processes associated with PPARg. The role of PPARg in inhibiting HCC metastases in vitro was further elucidated in an orthotopic HCC xenograft model. In this murine model, activation of PPARg suppressed HCC lung metastasis in nude mice. Surgical resection or liver transplantation is the curative mainstays of HCC management, however, post-operative recurrence predominantly related to metastasis remains a challenge. Our finding was supported by recent studies, which indicated that activation of PPARg inhibits metastasis of lung cancer (Reka et al, 2010) and non-small cell lung cancer (Choudhary et al, 2010) in vitro and in vivo. Collectively, our finding that activation of PPARg by rosiglitazone significantly suppresses metastatic potential could have a beneficial impact on the clinical practice and in adjuvant therapy of HCC after surgical resection and transplantation. The molecular mechanisms by which PPARg exerts its antiinvasive and anti-metastases functions in HCC have not yet been defined. To identify key regulators of PPARg-mediated antimetastatic effect in HCC, we utilised cDNA microarray and ChIP-PCR to study MHCC97L cells infected with Ad-PPARg, genes that were significantly altered in expression levels were then validated by RT-PCR and immunoblotting. We report that the suppression of cell invasion and migration mediated by PPARg was mediated via downregulation of MMPs (MMP9, MMP13), increased expression of TIMP3 and E-cadherin. Of which, MMP9 and MMP13 are members of extracellular proteinases with key functions in the formation and remodelling of tumour invasion (Khasigov et al, 2003) . Matrix metallopeptidase 9 has been described to promote tumour malignant progression, invasion, and metastatic spread by activating tumour growth factor-b (TGF-b) (Yu and Stamenkovic, 2000) . Whereas, MMP13 has a central role in the modulation of other MMPs (Leeman et al, 2002) such as stimulating pro-MMP9 activation (Knäuper et al, 1997) . Elevated MMP13 had been shown in various human malignancies including breast cancer, colorectal neoplasms, melanoma, and squamous head and neck tumours, particularly at the invading edge of such cancers; increased MMP13 expression was associated with poor prognosis, tumour aggressiveness, and metastases (Leeman et al, 2002; Luukkaa et al, 2006; Kondratiev et al, 2008; Chang et al, 2009 ).
Tissue inhibitors of metallo proteinase 3 is an important endogenous inhibitor of MMPs. Upregulation of TIMP3 expression by PPARg suggested its suppressive functions in tumour invasion and metastasis via suppressing of MMPs (Bachman et al, 1999 ; Wild et al, 2003) . Matrix metallopeptidase 9 and 13 are important mediators in the turnover of ECM and degradation of cell surface molecules such as E-cadherin; they have been described to promote cancer cell migration (Cowden Dahl et al, 2008) . Cell-cell adhesion molecule, E-cadherin, is also a key component of epithelial adherent junctions. Loss of E-cadherin expression is a hallmark of epithelial-tomesenchymal transition, a plausible mechanism of driving cancer progression and metastasis (Onder et al, 2008; Makrilia et al, 2009) . We demonstrate further that PPARg inhibits transcription of HPSE by direct binding to its promoter. Upregulation of HPSE has been associated with increased lymph node, as well as distant metastases (Sanderson et al, 2005) and reduced post-operative survival of cancer patients (Sato et al, 2004) .
The anti-metastasis function of PPARg in vitro also appeared to be associated with the downregulation of HGF by cDNA array. HGF is known to act as a multifunctional growth factor and is upregulated in many human cancers including HCC (Ljubimova et al, 1997; Maulik et al, 2002) . Hepotocyte growth factor drives epithelial cells to undergo EMT and can downregulate EMTassociated E-cadherin expression in murine liver tumour cells (Ding et al, 2010) . Also, HGF has been reported to stimulate MMP9 expression (Mizuno et al, 2005) and increase MMP3 promoter activity in HCC (Ozaki et al, 2003) , which can lead to increased cancer cell invasiveness (Reboul et al, 2001; Wang et al, 2007; Lee et al, 2010) . Notably, HGF activity may be mediated by MMPs (including MMP9 and MMP13) in the extracellular matrix, and thus induce HCC cells to proliferate and invade (Monvoisin et al, 2002; Mohammed et al, 2005) . In contrast, HGF may downmodulate TIMP-3 expression resulting in increased MMP accumulation, hence contributing to the invasiveness and aggressiveness in cancer cells (Castagnino et al, 1998) . Thus, the antimetastasis effect of PPARg in HCC may be in part related to the inhibition of HGF expression ( Figure 4C ).
Tumour suppressor genes, RB1 and SYK, have been reported to be dysfunctional in several cancers where aberrant expression levels appear to correlate with poor prognosis (Bailet et al, 2009; Kouraklis et al, 2009) . In contrast, overexpression of RB1 or SYK in several cancer cell types can inhibit tumour growth and reduce metastasis in mouse xenografts (Valente et al, 1996; Coopman et al, 2000) . Spleen tyrosine kinase also inhibits the motility of human breast cancer cells (Zhang et al, 2009 ) and promotes the formation of cell-cell contact through mediation of E-cadherin activity (Larive et al, 2009) . In the present study, we describe a near two-fold induction of SYK and impressive upregulation by four-fold of RB1 by PPARg in keeping with its proposed antimetastatic and -invasive effects.
In conclusion, activation of PPARg has demonstrated efficacy in suppressing HCC cell migration and invasion in vitro, and in inhibiting distant metastases from liver in an orthotopic HCC model in vivo. Peroxisome proliferator-activated receptor-gamma may provide a potential target for the prevention and treatment of metastatic HCC.
